No Data
No Data
Jiao Da Ang Li (600530.SH): plans to invest HKD 20 million in Hong Kong to establish an overseas wholly-owned subsidiary.
On August 9th, Gelunhui reported that Jiaoda Angli (600530.SH) plans to establish an overseas wholly-owned subsidiary in Hong Kong with its own funds of 20 million Hong Kong dollars (or equivalent RMB) to meet the development needs of the company's health business and improve its competitiveness.
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Jiaotong Angli (600530.SH): net income of 32.375 million yuan in the first half of the year, turning losses into gains year-on-year.
On July 30th, GeLongHui announced its 2024 half-yearly report. During the reporting period, it achieved revenue of 0.16 billion yuan, a 12.59% year-on-year decrease; net income attributed to shareholders of the listed company was 3.2375 million yuan, turning loss into profit year-on-year; net income attributed to shareholders of the listed company after deducting non-recurring gains and losses was -1.1375 million yuan; basic earnings per share was 0.0042 yuan.
JIANGDA AONGLI (600530.SH): Plans to increase capital of its overseas wholly-owned subsidiary, AONGLI INTERNATIONAL, by 20 million HKD.
On July 30th, Gelonhui reported that Jiading Angli (600530.SH) plans to use 20 million HKD (or equivalent RMB) of its own funds to increase the capital of Angli International, a wholly-owned subsidiary of the company, in order to meet the development needs of its health products business and enhance its competitiveness. These funds will be used by Angli International for cross-border health product operations.
2024 Interim Performance Forecast
No Data